Centessa Shareholders Approve Eli Lilly Acquisition Scheme
I'm LongbridgeAI, I can summarize articles.Centessa Pharmaceuticals shareholders overwhelmingly approved the acquisition scheme by Eli Lilly subsidiary LDH XV Corporation, with over 126 million votes in favor. The approval paves the way for the court-sanctioned transaction, subject to a final U.K. court hearing on June 22, 2026. Concurrently, shareholders passed all resolutions at the Annual General Meeting, including director reappointments and adoption of 2025 accounts without dividends, signaling strong support for the deal and governance.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
An update from Centessa Pharmaceuticals ( (CNTA) ) is now available.
On June 12, 2026, Centessa Pharmaceuticals’ shareholders overwhelmingly approved the court-sanctioned scheme of arrangement under the U.K. Companies Act through a Scheme Meeting, with 126,653,456 votes in favor and only 23,007 against, paving the way for Eli Lilly subsidiary LDH XV Corporation to acquire all issued and to be issued Centessa shares. At a concurrent general meeting, investors also authorized the board to implement the scheme and amend the company’s articles, while the 2026 Annual General Meeting saw all resolutions passed, including the reappointment of directors and KPMG as auditor and the adoption of 2025 accounts without a dividend, underscoring broad shareholder support ahead of a U.K. court hearing scheduled for June 22, 2026 to sanction the transaction.
Centessa reported strong shareholder turnout at both the Scheme Meeting and Company General Meeting, with 126,676,463 ordinary shares represented out of 154,731,309 eligible, satisfying quorum requirements and reinforcing legitimacy of the approval process. At the Annual General Meeting held the same day, 134,569,251 shares were present or represented by proxy, and shareholders backed all ordinary resolutions, including advisory approval of the 2025 directors’ remuneration report, signaling confidence in the company’s governance as it transitions toward acquisition by Eli Lilly outside the scope of the U.K. Takeover Code.
The most recent analyst rating on (CNTA) stock is a Hold
with a $42.00 price target.
To see the full list of analyst forecasts on Centessa Pharmaceuticals stock,
see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Neutral.
The score is held back mainly by weak financial performance (no TTM revenue, large ongoing losses, and heavy cash burn), partially offset by a strong low-leverage balance sheet. Technicals are constructive but appear stretched (RSI/Stoch elevated). The most supportive factor is the positive acquisition event with recent antitrust progress, though closing conditions remain.
To see Spark’s full report on CNTA stock,
click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a biotechnology company focused on developing pharmaceutical therapies, operating through a portfolio-based model aimed at advancing novel drug candidates. The company is listed with ordinary shares and follows U.K. corporate governance practices, including statutory audits, annual general meetings, and shareholder approvals for key corporate actions.
Average Trading Volume: 2,603,061
Technical Sentiment Signal: Buy
Current Market Cap: $6.15B
Learn more about CNTA stock on TipRanks’ Stock Analysis page.